Reata Pharmaceuticals Inc.

08/09/2022 | Press release | Distributed by Public on 08/09/2022 04:56

Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich’s Ataxia